Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
COVIDSurg, Collaborative;GlobalSurg, Collaborative.
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
Anaesthesia. 2021; 76(6): 748-758.
Doi: 10.1111/anae.15458
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
-
Andrianakis Alexandros
-
Belarmino Armin
-
Brinskelle Petra
-
Castellani Christoph
-
Cohnert Tina Ulrike
-
Fediuk Melanie
-
Fink Andrea
-
Holzmeister Clemens
-
Kahn Judith
-
Leithner Andreas
-
Lindenmann Jörg
-
Lumenta David Benjamin
-
Michelitsch Birgit
-
Nischwitz Sebastian Philipp
-
Puchwein Paul
-
Schemmer Peter
-
Singer Georg
-
Smolle-Juettner Freyja-Maria
-
Till Holger
-
Wolf Axel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231 patients (116 countries), 3127 patients (2.2%) had a pre-operative SARS-CoV-2 diagnosis. Adjusted 30-day mortality in patients without SARS-CoV-2 infection was 1.5% (95%CI 1.4-1.5). In patients with a pre-operative SARS-CoV-2 diagnosis, mortality was increased in patients having surgery within 0-2 weeks, 3-4 weeks and 5-6 weeks of the diagnosis (odds ratio (95%CI) 4.1 (3.3-4.8), 3.9 (2.6-5.1) and 3.6 (2.0-5.2), respectively). Surgery performed ≥ 7 weeks after SARS-CoV-2 diagnosis was associated with a similar mortality risk to baseline (odds ratio (95%CI) 1.5 (0.9-2.1)). After a ≥ 7 week delay in undertaking surgery following SARS-CoV-2 infection, patients with ongoing symptoms had a higher mortality than patients whose symptoms had resolved or who had been asymptomatic (6.0% (95%CI 3.2-8.7) vs. 2.4% (95%CI 1.4-3.4) vs. 1.3% (95%CI 0.6-2.0), respectively). Where possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. Patients with ongoing symptoms ≥ 7 weeks from diagnosis may benefit from further delay.
- Find related publications in this database (using NLM MeSH Indexing)
-
Adolescent - administration & dosage
-
Adult - administration & dosage
-
Aged - administration & dosage
-
Aged, 80 and over - administration & dosage
-
COVID-19 - administration & dosage
-
Child - administration & dosage
-
Child, Preschool - administration & dosage
-
Cohort Studies - administration & dosage
-
Female - administration & dosage
-
Humans - administration & dosage
-
Infant - administration & dosage
-
Internationality - administration & dosage
-
Male - administration & dosage
-
Middle Aged - administration & dosage
-
Practice Guidelines as Topic - administration & dosage
-
Prospective Studies - administration & dosage
-
SARS-CoV-2 - administration & dosage
-
Surgical Procedures, Operative - statistics & numerical data
-
Time - administration & dosage
-
Young Adult - administration & dosage
- Find related publications in this database (Keywords)
-
COVID-19
-
delay
-
SARS-CoV-2
-
surgery
-
timing